% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Galldiks:202241,
      author       = {Galldiks, Norbert and Langen, K. J. and Pope, W.},
      title        = {{F}rom the clinician's point of view - {W}hat is the status
                      quo of {PET} in patients with brain tumors?},
      journal      = {Neuro-Oncology},
      volume       = {17},
      number       = {11},
      issn         = {1522-8517},
      address      = {Oxford},
      publisher    = {Oxford Univ. Press},
      reportid     = {FZJ-2015-04530},
      pages        = {1434-1444},
      year         = {2015},
      abstract     = {The most common type of primary brain tumor is malignant
                      glioma. Despite intensive therapeutic efforts, the majority
                      of these neoplasms remain incurable. Imaging techniques are
                      important for initial tumor detection and comprise
                      indispensable tools for monitoring treatment. Structural
                      imaging using contrast-enhanced MRI is the method of choice
                      for brain tumor surveillance, but its capacity to
                      differentiate tumor from nonspecific tissue changes can be
                      limited, particularly with posttreatment gliomas. Metabolic
                      imaging using positron-emission-tomography (PET) can provide
                      relevant additional information, which may allow for better
                      assessment of tumor burden in ambiguous cases. Specific PET
                      tracers have addressed numerous molecular targets in the
                      last decades, but only a few have achieved relevance in
                      routine clinical practice. At present, PET studies using
                      radiolabeled amino acids appear to improve clinical
                      decision-making as these tracers can offer better
                      delineation of tumor extent as well as improved targeting of
                      biopsies, surgical interventions, and radiation therapy.
                      Amino acid PET imaging also appears useful for
                      distinguishing glioma recurrence or progression from
                      postradiation treatment effects, particularly radiation
                      necrosis and pseudoprogression, and provides information on
                      histological grading and patient prognosis. In the last
                      decade, the tracers O-(2-[18F]fluoroethyl)-L-tyrosine (FET)
                      and 3,4-dihydroxy-6-[18F]-fluoro-L-phenylalanine (FDOPA)
                      have been increasingly used for these indications. This
                      review article focuses on these tracers and summarizes their
                      recent applications for patients with brain tumors. Current
                      uses of tracers other than FET and FDOPA are also discussed,
                      and the most frequent practical questions regarding PET
                      brain tumor imaging are reviewed.},
      cin          = {INM-3 / INM-4},
      ddc          = {610},
      cid          = {I:(DE-Juel1)INM-3-20090406 / I:(DE-Juel1)INM-4-20090406},
      pnm          = {572 - (Dys-)function and Plasticity (POF3-572)},
      pid          = {G:(DE-HGF)POF3-572},
      typ          = {PUB:(DE-HGF)16},
      UT           = {WOS:000364783900003},
      pubmed       = {pmid:26130743},
      doi          = {10.1093/neuonc/nov118},
      url          = {https://juser.fz-juelich.de/record/202241},
}